A PHASE II, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF RO7790121 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- Diagnosis of Atopic Dermatitis

Exclusion Criteria:

- Prior or current treatment with any approved or investigational biologics

Conditions & Interventions

Interventions:
Drug: Afimkibart, Drug: Placebo
Conditions:
Dermatology (Skin, Hair & Nails)
Keywords:
Atopic Dermatitis, Clinics and Surgery Center (CSC)

More Information

Description: The purpose of this study is to learn about the efficacy and safety of RO7790121, which is a new medication being developed to treat people who have moderate to severe atopic dermatitis (AD). Participants will receive either the new medication or a placebo (doesn't contain any medicine) and the results will be compared. The total time of study treatment for an individual will be approximately 30 weeks.
Study Contact: Jaime Nugent - speck007@umn.edu
Principal Investigator: Paul Bigliardi
Phase: PHASE2
IRB Number: STUDY00025347